Andrew J Wagner MD PhD

Sarcoma

Associate Professor of Medicine, Dana-Farber Cancer Institute

450 Brookline AveBoston, MA 02215
Phone+1 617-632-5204
Fax+1 617-632-3408

Dr. Wagner is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wagner's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2005
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1997

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 1999 - 2028
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2015, 2017

Clinical Trials

Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors
COMPLETED
PHASE1
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
COMPLETED
PHASE2
Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia
TERMINATED
PHASE1

Publications & Presentations

PubMed

Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances.
Luyuan Li, Genevieve Bertolet, Josiane E Eid, William D Tap, Andrew J Wagner
Cancer Treatment Reviews. 2026-07-27
Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency.
Thierry Alcindor, David J Papke Jr, Vinayak Venkataraman, Michael J Wagner, Priscilla Merriam
JCO Precision Oncology. 2026-07-01
Management of multifocal and metastatic retroperitoneal sarcoma: an updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working grou...
Chiara Fabbroni, Edward W Johnston, Roberta Sanfilippo, Dirk C Strauss, Sylvie Bonvalot
Cancer Treatment Reviews. 2026-02-01

Lectures

ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open l...
2019 ASCO Annual Meeting - 6/1/2019
Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su)...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Bezuclastinib Plus Sunitinib Prolongs Progression-Free Survival in Advanced Gastrointestinal Stromal TumorsMay 31st, 2026
TURALIO® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ENLIVEN Phase 3 TrialJuly 9th, 2025
TURALIO® Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of ENLIVEN Phase 3 TrialJuly 9th, 2025